Seminary
Inhibition of catechol catechol-O-methyltransferase (COMT) in the brains of subjects treated with l-DOPA (l-3,4-dihydroxylphenylalanine) and an aromatic amino acid decarboxylase (AADC) inhibitor is suggested to cause an increase of l-DOPA, which might lead to oxidative damage through enhanced formation of free radicals. To investigate this hypothesis, the acute effects of two doses of the systemically administered COMT inhibitors entacapone (peripheral) and tolcapone (peripheral and central) on the extracellular formation of hydroxyl radicals in vivo following treatment with l-DOPA and the AADC inhibitor carbidopa were examined. The formation of extracellular hydroxyl radicals were determined by the measurement of 2,3-dihydroxybenzoic acid (2,3-DHBA), a reaction product of hydroxyl radicals with sodium salicylate, using microdialysis in the striatum of anesthetised rats. The COMT inhibitors were administered together with 50mg/kg i.p. carbidopa as 5% gum arabic suspensions intraperitoneally (i.p.) at doses of 0, 1.0, and 10mg/kg body weight to a total of 36 male HAN-Wistars rats, l-DOPA was injected i.p. 40min after drugs of interest. Microdialysis samples were collected every 20 min for 400 min at a perfusion rate of 1µl/min. Systemically administered 10mg/kg tolcapone, but not entacapone, induced an increase in hydroxyl radical formation in the striatum of anesthetised rats following treatment with l-DOPA/carbidopa. The increase in hydroxyl radical formation was reflected by higher extracellular concentrations of the hydroxylate product of salicylate, 2,3-DHBA, peaking at 192% of baseline at the end of the observation period. Similar results were also found using the AUC (area under the curve) value estimated for the observation period. We conclude that the increase in hydroxyl radical formation is likely to result from an increased rate of monoamine oxidase-mediated and non-enzymatic (autoxidation) dopamine metabolism following increased central availability caused by reduction in COMT-mediated metabolism. We cannot, however, exclude the possibility that hydroxyl radicals are produced by tolcapone as a result of uncoupling mitochondrial oxidative phosphorylation.
Similar content being viewed by others
Abbreviations
- ADDC :
-
aromatic amino acid decarboxylase
- AUC :
-
area under the curve
- ANOVA :
-
analysis of variance
- COMT :
-
catechol-O-methyltransferase
- 2,3-DHBA :
-
2,3-dihydroxybenzoic acid
- l-DOPA:
-
levodopa, l-3,4-didydroxylphenylalanine
- DOPAC :
-
3,4-dihydroxyphenylacetic acid
- HPLC :
-
high pressure liquid chromatography
- HVA :
-
homovanillic acid
- i.p. :
-
intraperitoneally
- MAO :
-
monoamine oxidase
- 3-MT :
-
3-methoxytyramine
- NMDA :
-
N-methyl-d-aspartate
- OMD :
-
3-O-metyl-DOPA
- PD :
-
Parkinson’s disease
- SPECT :
-
single photon emission computed tomography
References
Abercrombie ED, Bonatz AE, Zigmond MJ (1990) Effects of l-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res 525: 36–40
Acquas E, Carboni E, De Ree RAH, Da Prada M, Di Chiara G (1992) Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro 40,7592. J Neurochem 59: 326–330
Brannan T, Prikhojan A, Yahr MD (1997) Peripheral and central inhibitors of catechol-O-methyltransferase: effects on liver and brain COMT activity and l-DOPA metabolism. J Neural Transm 104: 77–87
Brown EE, Damsma G, Gumming P, Fibiger HC (1991) Interstitial 3-methoxytyrarnine reflects striatal dopamine release: an in vivo microdialysis study. J Neurochem 57: 701–707
Camp DM, Loeffler DA, Le Witt PA (2000) l-DOPA does not enhance hydroxyl radical formation in the nigrostriatal dopamine system of rats with unilateral 6-hydroxydop- amine lesion. J Neurochem 74: 1229–1240
Fahn S (1997) Levodopa-induced neurotoxicity. Does it represent a problem for the treatment of Parkinson’s disease? CNS Drugs 8: 376–393
Gerlach M, Xiao A, Heim C, Lan J, God R, Feineis D, Bringmann G, Riederer P, Sontag K-H (1998) l-Trichloromethyl-l,2,3,4-tetrahydro-²-carboline (TaClo) increases extracellular serotonin and stimulates hydroxyl radical production. Neurosci Lett 257: 17–20
Götz ME, Kiinig G, Riederer P, Youdim MBH (1994) Oxidative stress: free radical production in neuronal degeneration. Pharmac Ther 63: 37–122
Kaakkola S, Wurtman RJ (1992) Effects of catechol-O-methyltransferase inhibitors on striatal dopamine metabolism. Brain Res 587: 241–249
Kaakkola S, Wurtman RJ (1993) Effects of catechol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum. J Neurochem 60: 137–144
Kaakkola S, Gordin A, Männistö PT (1994) General properties and clinical possibilities of new selective inhibitors of catechol-O-methyltransferase. Gen Pharmacol 25: 813–824
Karhunen T, Tilgmann C, Ulmanen I, Panula P (1995) Catechol-O-methyltransferase (COMT) in rat brain: immunoelectron microscopic study with an antiserum against rat recombinant COMT protein. Neurosci Lett 187: 57–60
Kastner A, Anglade P, Damier P, Javoy-Agid F, Bromet N, Agid Y, Hirsch EC (1994) Immunohistochemical study of catechol-O-methyltransferase in the human mesostriatal system. Neuroscience 62: 449–457
Kuhn W, Woitalla D, Gerlach M, Russ H, Müller T (1998) Tolcapone and neurotoxicity in Parkinson’s disease. Lancet 352: 1313–1314
Männistö PT, Tuomainen P, Tuominen RK (1992a) Different in vivo properties of three new inhibitors of catechol-O-methyltransferase in the rat. Br J Pharmacol 105: 569–574
Männistö PT, Ulmanen I, Lundström K, Taskinen J, Tenhunen J, Kaakkola S (1992b) Characteristics of catechol-O-methyltransferase (COMT) and properties of selective inhibitors. Prog Drug Res 39: 291–350
McNeely W, Davis R (1997) Entacapone. CNS Drugs 8: 79–88
Montastruc JL, Rascol O, Senard JM (1999) Treatment of Parkinson’s disease should begin with a dopamine agonist. Mov Disord 14: 725–730
Montgomery J, Ste-Marie L, Boismenu D, Vachon L (1995) Hydroxylation of aromatic compounds as indices of hydroxyl radical production: a cautionary note revisited. Free Radie Biol Med 19: 927–933
Myllylä VV, Sotaniemi KA, Hakulinen P, Mäki-Jkola O, Heinonen EH (1997) Selegiline as the primary treatment of Parkinson’s disease — a long-term double-blind study. Acta Neurol Scand 95: 211–218
Napolitano A, Zürcher G, Da Prada M (1995) Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of l-DOPA and dopamine in rats. Eur J Pharmacol 273: 215–221
Nissinen E, Kaheinen P, Penttilä KE, Kaivola J, Linden I-B (1997) Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson’s disease, does not impair mitochondrial energy production. Eur J Pharmacol 340: 287–294
Patthy M, Kiraly I, Sziraki I (1995) Separation of dihydroxybenzoates, indicators of in-vivo hydroxyl free radical formation, in the presence of transmitter amines and some metabolites in rodent brain, using high performance liquid chromatography with electrochemical detection. J Chromatogr B 664: 247–252
Paxinos G, Watson C (1982) The rat brain in stereotaxic coordinates, 2nd ed. Academic Press, London
Spencer CM, Benfield P (1996) Tolcapone. CNS Drugs 5: 475–481
Staffen W, Mair A, Unterrainer J, Trinka E, Ladurner G (2000) Measuring the progression of idiopathic Parkinson’s disease with [I-123] beta-CIT SPECT. J Neural Transm 107: 543–552
Wachtel SR, Abercrombie ED (1994) l-3,4-dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors. J Neurochem 63: 108–117
Zürcher G, Dingemanse J, Da Prada M (1991) Ro-40-7592, a potent inhibitor of extracerebral and brain catechol-O-methyltransferase: preclinical and clinical findings. In: Agnoli A, Campanella G (eds) New developments in therapy of Parkinson’s disease. John Libbey CIC, Roma, pp 37–43
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gerlach, M., Xiao, A.Y., Kuhn, W. et al. The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in l-DOPA/carbidopa treated rats. J Neural Transm 108, 189–204 (2001). https://doi.org/10.1007/s007020170087
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s007020170087